Sana Biotechnology Q4 adjusted EPS misses estimates

Sana Biotechnology

03/03/2026 21:39

Overview

Biotech firm reported Q4 adjusted EPS miss analyst expectations

Raised $133.7 mln from stock sales, cash runway into late 2026

Outlook

Sana anticipates cash runway into late 2026

Result Drivers

RESEARCH AND DEVELOPMENT EXPENSES: For the three months ended December 31, 2025, research and development expenses, inclusive of non-cash expenses, were $34.9 million

Company press release: ID:nGNX25tq5m

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Adjusted EPS
Miss
-$0.16
-$0.13 (7 Analysts)
Q4 EPS
-$0.21
Q4 Operating Expenses
$61.20 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Sana Biotechnology Inc is $7.50, about 80.7% above its March 2 closing price of $4.15

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)